NCT02727205View on ClinicalTrials.gov

Irritation and Sensitization Potential of Repeat Applications of Rotigotine Patch

PHASE1CompletedINTERVENTIONAL
Enrollment

260

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

October 31, 2013

Study Completion Date

October 31, 2013

Conditions
Bioequivalence - Irritation and Sensitization Potential of Transdermal Patch
Interventions
DRUG

Rotigotine Transdermal System

Trial Locations (2)

33014

Clinical Pharmacology of Miami, Inc., Miami

L4W 1A4

Inflamax Research Inc., Mississauga

All Listed Sponsors
lead

Inflamax Research Incorporated

INDUSTRY

NCT02727205 - Irritation and Sensitization Potential of Repeat Applications of Rotigotine Patch | Biotech Hunter | Biotech Hunter